Lv3
342 积分 2023-12-05 加入
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
10天前
已完结
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project
19天前
已完结
Safety and Tolerability of c-MET Inhibitors in Cancer
2个月前
已完结
THE GASTROINTESTINAL ABSORPTION OF ORAL IRON-DEXTRAN AND FERROUS SULFATE
2个月前
已完结
Development of a Crohn's Disease Activity Index
2个月前
已完结
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
4个月前
已完结
[Evaluation considerations for using surrogate endpoints in anticancer clinical trials]
4个月前
已完结
SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant
5个月前
已完结
Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review
5个月前
已完结
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
6个月前
已完结
皖公网安备34019202002308
